Business
Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical Meetings
WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate
About this update from Korro Bio, Inc.
[{"type":"text","content":" WOBURN, Mass.--(BUSINESS WIRE)--\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Company management will be presenting at the following investor conferences and medical meetings:\n\n\n\nAmerican Academy of Otolaryngology – Head & Neck Surgery (AAO-HNS) 2020 Virtual Annual Meeting & OTO Experience, September 13, 2020, 3:00 p.m. ET\n\n\nCantor Fitzgerald Global Virtual Global Healthcare Conference, September 17, 2020, 4:00 p.m. ET\n\n\nOppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit, September 22, 2020, 10:00 a.m. ET\n\n\n\nThe Cantor Fitzgerald and Oppenheimer investor presentations will be available via webcast and may be viewed on the Investors & Media section of the Frequency website. A replay of the presentations will be posted on the Frequency website and made available for at least 30 days following each event.\n\n\nAbout Frequency Therapeutics\n\n\nFrequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. FX-322 is being evaluated in an ongoing Phase 2a clinical study in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.\n\n\nHeadquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, Partners Healthcare and the Massachusetts Institute of Tec...